Navigation path

TB-DRUG


Tuberculosis

A SME-STREP for Tuberculosis Drug Development
Framework programme:
6
Call:
3
Project number:
LSHP-CT-2006-037217
EC contribution:
€ 1,945,000
Duration:
36 Months
Type:
STREP
Starting date:
December 2006

Keywords: Microbiology, Infections, Pharmaceutical chemistry, Drug targets, Biochemistry, Structural biology, Tuberculosis

Summary:

The primary objective of this project is to identify suitable drug targets and to discover lead compounds suitable for development into new drugs active against tuberculosis.
The plan of action is to:

  1. Express and purify each protein being targeted using available expression systems;
  2. Determine the structure of each protein by X-ray crystallography;
  3. Develop biochemical assays suitable for adaptation to high-throughput screening (HTS);
  4. Screen for and identify inhibitors for each protein where a suitable assay has been developed;
  5. Assess the effectiveness of the best inhibitors identified against Mycobacterium tuberculosis in vitro, and;
  6. Optimise lead compounds by medicinal chemistry.

Background:

Tuberculosis (TB) causes more deaths worldwide than almost any other infectious disease, with nearly two million deaths per year and devastating impact on developing countries. More effective means of medical intervention are required, both to reduce the number of deaths from tuberculosis and to allow for more effective treatment of drug-resistant infections.

[+] Read More